{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T02:03:11Z","timestamp":1784599391751,"version":"3.55.0"},"reference-count":14,"publisher":"ARAN Ediciones","issue":"4","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.hipert.2024.06.004","type":"journal-article","created":{"date-parts":[[2024,7,10]],"date-time":"2024-07-10T09:16:57Z","timestamp":1720603017000},"page":"226-231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prescripci\u00f3n de antihipertensivos en personas con diabetes tipo 2 en Andaluc\u00eda y recomendaciones SEH-LELHA 2022: evaluaci\u00f3n del coste y uso"],"prefix":"10.20960","volume":"41","author":[{"given":"D.","family":"Mart\u00edn-Enguix","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.C.","family":"Aguirre Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Guisasola C\u00e1rdenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.N.","family":"Generoso Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hidalgo Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"S\u00e1nchez Cambronero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Gonz\u00e1lez Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"8588","reference":[{"key":"10.1016\/j.hipert.2024.06.004_bib0075","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.cjca.2017.12.005","article-title":"Diabetes, hypertension, and cardiovascular disease: Clinical insights and vascular mechanisms","volume":"34","author":"Petrie","year":"2018","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hipert.2024.06.004_bib0080","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.hipert.2022.09.002","article-title":"Gu\u00eda pr\u00e1ctica sobre el diagn\u00f3stico y tratamiento de la hipertensi\u00f3n arterial en Espa\u00f1a, 2022. Sociedad Espa\u00f1ola de Hipertensi\u00f3n - Liga Espa\u00f1ola para la Lucha contra la Hipertensi\u00f3n Arterial (SEH-LELHA)","volume":"39","author":"Gorostidi","year":"2022","journal-title":"Hipertens Riesgo Vasc"},{"key":"10.1016\/j.hipert.2024.06.004_bib0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3390\/jpm12010087","article-title":"Precision medicine for hypertension patients with type 2 diabetes via reinforcement learning","volume":"12","author":"Oh","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.hipert.2024.06.004_bib0090","doi-asserted-by":"crossref","first-page":"140","DOI":"10.24038\/mgyf.2018.050","article-title":"Grado de control cardiovascular en pacientes diab\u00e9ticos tipo 2 de acuerdo con objetivos individualizados: Estudio \u201cCONCARDIA\u201d","volume":"7","author":"Aguirre Rodr\u00edguez","year":"2018","journal-title":"Med Gen Fam"},{"key":"10.1016\/j.hipert.2024.06.004_bib0095","unstructured":"Gu\u00eda farmacoterap\u00e9utica de Atenci\u00f3n Primaria al d\u00eda. Consejer\u00eda de Salud y Consumo. Servicio Andaluz de Salud: p. 97 https:\/\/www.sspa.juntadeandalucia.es\/servicioandaluzdesalud\/sites\/default\/files\/sincfiles\/wsas-media-mediafile_sasdocumento\/2022\/guia_farmacologica_at_aldia_agosto_2022.pdf"},{"key":"10.1016\/j.hipert.2024.06.004_bib0100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3399\/bjgp20X708053","article-title":"Diagnosis and management of hypertension in adults: NICE guideline update 2023","volume":"70","author":"Jones","year":"2020","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.hipert.2024.06.004_bib0105","unstructured":"Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios. Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios 2022 [consultado 10 Dic 2023]. Disponible en https:\/\/www.aemps.gob.es\/."},{"key":"10.1016\/j.hipert.2024.06.004_bib0110","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/dom.13512","article-title":"Atrial fibrillation and type 2 diabetes: Prevalence, etiology, pathophysiology and effect of anti-diabetic therapies","volume":"21","author":"Bell","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.hipert.2024.06.004_bib0115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.2174\/1570161117666190405165151","article-title":"Macrovascular complications of type 2 diabetes mellitus","volume":"18","author":"Viigimaa","year":"2020","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.hipert.2024.06.004_bib0120","doi-asserted-by":"crossref","first-page":"146","DOI":"10.4093\/dmj.2020.0282","article-title":"Epidemiology, pathophysiology, diagnosis and treatment of heart failure in diabetes","volume":"45","author":"Park","year":"2021","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.hipert.2024.06.004_bib0125","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1157\/13070510","article-title":"Documento de Consenso de Expertos sobre bloqueadores de los receptores \u00df-adren\u00e9rgicos","volume":"58","author":"L\u00f3pez-Send\u00f3n","year":"2005","journal-title":"Rev Esp Cardiol."},{"key":"10.1016\/j.hipert.2024.06.004_bib0130","doi-asserted-by":"crossref","first-page":"102066","DOI":"10.1016\/j.semerg.2023.102066","article-title":"Diabetes tipo 2 en Andaluc\u00eda: uso de recursos y coste econ\u00f3mico","volume":"49","author":"Aguirre Rodr\u00edguez","year":"2023","journal-title":"Semergen"},{"key":"10.1016\/j.hipert.2024.06.004_bib0135","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1007\/s00228-021-03163-4","article-title":"Cost effectiveness of antihypertensive drugs and treatment guidelines","volume":"77","author":"Ku\u010dan","year":"2021","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.hipert.2024.06.004_bib0140","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/S0300-8932(09)70158-7","article-title":"Uso de espironolactona o doxazosina en pacientes con hipertensi\u00f3n arterial refractaria","volume":"62","author":"Rodilla","year":"2009","journal-title":"Rev Esp Cardiol"}],"container-title":["Hipertensi\u00f3n y Riesgo Vascular"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183724000837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1889183724000837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:15:36Z","timestamp":1784596536000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1889183724000837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1889183724000837"],"URL":"https:\/\/doi.org\/10.1016\/j.hipert.2024.06.004","relation":{},"ISSN":["1889-1837"],"issn-type":[{"value":"1889-1837","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescripci\u00f3n de antihipertensivos en personas con diabetes tipo 2 en Andaluc\u00eda y recomendaciones SEH-LELHA 2022: evaluaci\u00f3n del coste y uso","name":"articletitle","label":"Article Title"},{"value":"Hipertensi\u00f3n y Riesgo Vascular","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hipert.2024.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 SEH-LELHA. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}